News Analyses

In the scientific literature:

The “My-Health” Revolution: Communication Challenges in the Age of Personalized Medicine

If personalized medicine is ever going to be realized, it needs to address far more than scientific hurdles. The collaborative model that is solving the science needs to applied just as rigorously in communications between and among all stakeholders.
Read More  

Multiple Signatures of Breast Cancer

The power of current microarray technology to find genetic “signatures” of any given disease has resulted in a flurry of published results. These papers are undoubtedly just the tip of the iceberg. But what does it mean when very different genetic signatures are associated with one particular disease?
Read More

Meaningful silence

The most common of the millions of single nucleotide polymorphisms (SNPs) in the human genome are the so-called “silent” SNPs, or changes that do not affect the amino acid sequence of the protein they encode. These SNPs have been useful as tags for combing through the genome for disease-associated genes, but now it appears that they may be players in disease in their own right.
Read More

In the Press:

FDA responds to the Institute of Medicine Report

In September 2006, the Institute of Medicine (IOM) delivered a report on the state of the Food and Drug Agency’s (FDA) drug safety procedures. In response to the IOM report, which the FDA solicited, FDA Commissioner Andrew von Eschenbach outlined FDA’s improvement plan on January 30, 2007.
Read More